Prakantant alfa (Poractantum alfa)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Surfactants

Included in the formulation
  • Kurosurf®
    suspension e / tracheal. 
    Torrex Chiesi Pharma GmbH     Austria
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    R.07.A.A   Pulmonary surfactants

    R.07.A.A.02   Phospholipids, natural

    Pharmacodynamics:

    The drug fills the lack of endogenous pulmonary surfactant, stabilizes the alveoli, reduces the surface tension in the lungs, promotes adequate gas exchange in the lungs.

    The surfactant film has surface-active properties, is located on the interface between the air-liquid phases in the alveoli, regulates the surface tension with a change in their volume. Stimulates the production of endogenous surfactant in functionally immature lung preterm infants. Participates in the exchange of gases and liquids through the air-blood barrier, the removal of foreign particles from the surface of the alveoli, the protection of elements their walls from the damaging effects of oxidants and peroxides.

    Pharmacokinetics:

    After intratracheal administration, the main amount is retained in the lungs. The half-life period is 67 hours.

    Indications:

    Respiratory distress syndrome of newborns weighing more than 700 grams.

    ICD-10

    XVI.P20-P29.P22   Breathing disorder in a newborn [distress]

    Contraindications:
    • Hypersensitivity.
    • Hemorrhage in the ventricles of the brain.
    • Pneumothorax, interstitial emphysema, pneumomediastinum.
    Carefully:

    There is no data.

    Pregnancy and lactation:

    Not applicable in pregnant and lactating women.

    Dosing and Administration:

    Intratracheal in intubated children with artificial ventilation. The dose is set individually.

    The initial single dose is 100-200 mg / kg (1.25-2.5 ml / kg), again - 1 or 2 times at a dose of 100 mg / kg with an interval of at least 12 hours. The maximum total dose is 300-400 mg / kg.

    Side effects:
    • Allergic reactions
    • Pulmonary haemorrhage
    • Retinopathy (with a rapid increase in the partial pressure of oxygen in the blood)
    Overdose:

    Not described. Treatment is symptomatic. In case of an overdose, the maximum possible aspiration of suspended contents from the lungs, normalization of water-electrolyte balance, maintenance of vital functions.

    Interaction:

    Not described.

    Special instructions:

    The drug can be used by physicians with the necessary qualifications (treatment, resuscitation and clinical observation of premature infants) and with appropriate equipment (IVL, monitoring oxygen in the arterial blood). Immediately after administration, it is possible to increase the extensibility of the lungs, which determines the need for rapid reconfiguration of the ventilation values. Restoration of gas exchange in the alveoli can stimulate an increase in the oxygen level in the arterial blood (a decrease in its concentration in the gas mixture is required).

    Before taking the drug should be carried out correction of arterial hypotension, acidosis, anemia, hypothermia, hypoglycemia.

    In the case of reflux, the administration of the drug must be stopped.

    During the administration of the drug, it is necessary to monitor the patient's condition for immediate assistance in the event of undesirable reactions.

    Instructions
    Up